{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:05:59Z","timestamp":1785557159860,"version":"3.56.0"},"reference-count":33,"publisher":"Japanese Society of Radiological Technology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nippon Hoshasen Gijutsu Gakkai Zasshi","Jpn. J. Radiol. Technol."],"published-print":{"date-parts":[[2021]]},"DOI":"10.6009\/jjrt.2021_jsrt_77.1.32","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T17:07:32Z","timestamp":1611076052000},"page":"32-40","source":"Crossref","is-referenced-by-count":2,"title":["Cross-validation of Quantitative Analytical Software Using 18F-florbetapir PET Imaging","&lt;sup&gt;18&lt;\/sup&gt;F-florbetapir \u30a2\u30df\u30ed\u30a4\u30c9 PET \u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u306e\u5b9a\u91cf\u89e3\u6790\u30bd\u30d5\u30c8\u30a6\u30a7\u30a2\u306e\u4ea4\u5dee\u691c\u8a3c"],"prefix":"10.6009","volume":"77","author":[{"given":"Kei","family":"Wagatsuma","sequence":"first","affiliation":[{"name":"Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Miwa","sequence":"additional","affiliation":[{"name":"School of Health Science, International University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyuki","family":"Sakata","sequence":"additional","affiliation":[{"name":"Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishii","sequence":"additional","affiliation":[{"name":"Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4040","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer\u02bcs disease: recommendations from the National Institute on Aging-Alzheimer\u02bcs Association workgroups on diagnostic guidelines for Alzheimer\u02bcs disease. Alzheimers Dement 2011; 7(3): 280-292.","DOI":"10.1016\/j.jalz.2011.03.003"},{"key":"2","unstructured":"2) Rowe CC, Villemagne VL. Brain amyloid imaging. J Nucl Med 2013; 41(1): 11-18."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Degenhardt EK, Witte MM, Case MG, et al. Florbetapir F18 PET amyloid neuroimaging and characteristics in patients with mild and moderate Alzheimer dementia. Psychosomatics 2016; 57(2): 208-216.","DOI":"10.1016\/j.psym.2015.12.002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Fleisher AS, Chen K, Liu X, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011; 68(11): 1404-1411.","DOI":"10.1001\/archneurol.2011.150"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with\u00a0 alzheimer&apos;s\u00a0 disease\u00a0 and\u00a0 cognitively\u00a0 normal\u00a0 subjects. J Nucl Med 2012; 53(3): 378-384.","DOI":"10.2967\/jnumed.111.090340"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Chiao P, Bedell BJ, Avants B, et al. Impact of reference and target region selection on amyloid PET SUV ratios in the phase 1b PRIME study of aducanumab. J Nucl Med 2019; 60(1): 100- 106.","DOI":"10.2967\/jnumed.118.209130"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer&apos;s disease with Pittsburgh Compound-B. Ann Neurol 2004; 55(3): 306-319.","DOI":"10.1002\/ana.20009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Wong DF, Rosenberg PB, Zhou Y, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand <sup>18<\/sup>F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010; 51 (6): 913-920.","DOI":"10.2967\/jnumed.109.069088"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Minoshima S, Drzezga AE, Barthel H, et al. SNMMI procedure standard\/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med 2016; 57(8): 1316-1322.","DOI":"10.2967\/jnumed.116.174615"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) \u4e09\u8f2a\u5efa\u592a\uff0c\u6211\u59bb\u6167\uff0c\u5c71\u5c3e\u5929\u7fd4\uff0c\u4ed6\uff0e\u30a2\u30df\u30ed\u30a4\u30c9 PET \u306e\u5b9a\u91cf\u8a55\u4fa1\u306b\u95a2\u3059\u308b\u7814\u7a76\uff0e\u65e5\u653e\u6280\u5b66\u8a8c 2017; 73(11); 1165-1174.","DOI":"10.6009\/jjrt.2017_JSRT_73.11.1165"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Saint-Aubert L, Nemmi F, P\u00e9ran P, et al. Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging 2014; 41(5): 836-843.","DOI":"10.1007\/s00259-013-2656-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) \u8d64\u677e\u525b\uff0c\u5927\u897f\u7ae0\u4ec1\uff0c\u76f8\u7530\u4e00\u6a39\uff0c\u4ed6\uff0e\u8a8d\u77e5\u75c7\u3092\u5bfe\u8c61\u3068\u3057\u305f\u30a2\u30df\u30ed\u30a4\u30c9 PET \u306b\u304a\u3051\u308b\u64ae\u50cf\u6280\u8853\u3068\u753b\u50cf\u89e3\u6790\uff0e\u65e5\u653e\u6280\u5b66\u8a8c2017; 73(4): 298-308.","DOI":"10.6009\/jjrt.2017_JSRT_73.4.298"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Hutton C, Declerck J, Mintun MA, et al. Quantification of <sup>18<\/sup>F-florbetapir PET: comparison of two analysis methods. Eur J Nucl Med Mol Imaging 2015; 42(5): 725-732.","DOI":"10.1007\/s00259-015-2988-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Landau SM, Breault C, Joshi AD, et al. Amyloid-\u03b2 imaging\u00a0with\u00a0\u00a0 Pittsburgh\u00a0compound\u00a0B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med 2013; 54 (1): 70-77.","DOI":"10.2967\/jnumed.112.109009"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tuszynski T, Rullmann M, Luthardt J, et al. Evaluation of software tools for automated identification of neuroanatomical structures in quantitative \u03b2-amyloid PET imaging to diagnose Alzheimer&apos;s disease. Eur J Nucl Med Mol Imaging 2016; 43(6): 1077-1087.","DOI":"10.1007\/s00259-015-3300-6"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Choi WH, Um YH, Jung WS, et al. Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro. Ann Nucl Med 2016; 30(10): 682-689.","DOI":"10.1007\/s12149-016-1115-6"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Joshi AD, Pontecorvo MJ, Lu M, et al. A semiautomated method for quantification of F 18 florbetapir PET images. J Nucl Med 2015; 56(11): 1736-1741.","DOI":"10.2967\/jnumed.114.153494"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nakano M, Nakamura T, Takita Y, et al. Radiation dosimetry and pharmacokinetics of florbetapir (<sup>18<\/sup>F) in Japanese subjects. Ann Nucl Med 2019; 33(8): 639-645.","DOI":"10.1007\/s12149-019-01366-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Senda M, Yamamoto Y, Sasaki M, et al. An exploratory efficacy study of the amyloid imaging agent [<sup>18<\/sup>F]flutemetamol in Japanese subjects. Ann Nucl Med 2015; 29(5): 391-399.","DOI":"10.1007\/s12149-015-0957-7"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Lancaster JL Rainey LH, Summerlin JL, et al. Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward-transform method. Hum Brain Mapp 1997; 5(4): 238-242.","DOI":"10.1002\/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp 2000; 10(3): 120-131.","DOI":"10.1002\/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8"},{"key":"22","unstructured":"22) Breault C, Piper J, Joshi AD, et al. Correlation between two methods of florbetapir PET quantitative analysis. Am J Nucl Med Mol Imaging 2017; 7(3): 84-91."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u03b2 plaques: a prospective cohort study. Lancet Neurol 2012; 11(8): 669-678.","DOI":"10.1016\/S1474-4422(12)70142-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) \u4e0b\u4e95\u4fca\u5178\uff0e\u8a55\u4fa1\u306e\u7d76\u5bfe\u4fe1\u983c\u6027\uff0e\u7406\u7642\u79d1 2011; 26(3): 451-461\uff0e","DOI":"10.1589\/rika.26.451"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Harn NR, Hunt SL, Hill J, et al. Augmenting amyloid PET interpretations with quantitative information improves consistency of early amyloid detection. Clin Nucl Med 2017; 42(8): 577-581.","DOI":"10.1097\/RLU.0000000000001693"},{"key":"26","unstructured":"26) \u65e5\u672c\u6838\u533b\u5b66\u4f1a\uff0c\u65e5\u672c\u8a8d\u77e5\u75c7\u5b66\u4f1a\uff0c\u65e5\u672c\u795e\u7d4c\u5b66\u4f1a \u7de8\uff0e\u30a2\u30df\u30ed\u30a4\u30c9 PET \u30a4\u30e1\u30fc\u30b8\u30f3\u30b0\u5264\u306e\u9069\u6b63\u4f7f\u7528\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 \u6539\u8a02\u7b2c 2 \u7248\uff0e2017."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Pontecorvo MJ, Arora AK, Devine M, et al. Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. Eur J Nucl Med Mol Imaging 2017; 44(5): 825-837.","DOI":"10.1007\/s00259-016-3601-4"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Auvity S, Tonietto M, Caill\u00e9 F, et al. Repurposing radiotracers for myelin imaging:\u00a0 a\u00a0 study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB. Eur J Nucl Med Mol Imaging 2020; 47(2): 490-501.","DOI":"10.1007\/s00259-019-04516-z"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Frisoni GB, Lorenzi M, Caroli A, et al. In vivo mapping of amyloid toxicity in Alzheimer disease. Neurology 2009; 72 (17): 1504-1511.","DOI":"10.1212\/WNL.0b013e3181a2e896"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ch\u00e9telat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67(3): 317-324.","DOI":"10.1002\/ana.21955"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Jack CR, Lowe VJ, Senjem ML, et al. <sup>11<\/sup>C PiB and structural MRI provide complementary information in imaging of Alzheimer&apos;s disease and amnestic mild cognitive impairment. Brain 2008; 131(Pt 3): 665-680.","DOI":"10.1093\/brain\/awm336"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to hippocampal-mediated \u03b2-amyloid deposition in elderly subjects. Brain 2009; 132(Pt 5): 1310-1323.","DOI":"10.1093\/brain\/awn320"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Oh H, Madison C, Villeneuve S, et al. Association of gray matter atrophy with age, \u03b2-amyloid, and cognition in aging. Cereb Cortex 2014; 24(6): 1609-1618.","DOI":"10.1093\/cercor\/bht017"}],"container-title":["Japanese Journal of Radiological Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jjrt\/77\/1\/77_2021_JSRT_77.1.32\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T03:47:53Z","timestamp":1785556073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jjrt\/77\/1\/77_2021_JSRT_77.1.32\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.6009\/jjrt.2021_jsrt_77.1.32","relation":{},"ISSN":["0369-4305","1881-4883"],"issn-type":[{"value":"0369-4305","type":"print"},{"value":"1881-4883","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]},"article-number":"2021_JSRT_77.1.32"}}